Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 9/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | REN | P00797 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238628 | 1.00 | DPP4 (0.67) | DPP4ALDH1A1SMN1; SMN2ACEITGB3 | |
| SCHEMBL3223268 | 1.00 | DPP4 (0.67) | DPP4ALDH1A1SMN1; SMN2ACEITGB3 | |
| SCHEMBL3238359 | 1.00 | DPP4 (0.67) | DPP4ALDH1A1SMN1; SMN2ACEITGB3 | |
| SCHEMBL6435743 | 0.91 | DPP4 (0.58) | DPP4ALDH1A1SMN1; SMN2 | |
| SCHEMBL6435738 | 0.91 | DPP4 (0.58) | DPP4ALDH1A1SMN1; SMN2 | |
| SCHEMBL31376320 | 0.90 | DPP4 (0.65) | DPP4ALDH1A1SMN1; SMN2ACEF2 | |
| SCHEMBL5992939 | 0.85 | DPP4 (0.60) | DPP4ALDH1A1KDM4EF2 | |
| SCHEMBL13014739 | 0.84 | DPP4 (0.58) | DPP4F2 | |
| SCHEMBL6437308 | 0.84 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2ACEITGB3ITGB1 | |
| SCHEMBL6437305 | 0.84 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2ACEITGB3ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010027564-A2 | AMIDO ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-03-11 | — | — | WO | claimed |
| US-20100061960-A1 | Amido Anti-Viral Compounds, Compositions, And Methods Of Use | SCHMITZ FRANZ ULRICH | 2010-03-11 | — | — | US | claimed |
| WO-2010027564-A2 | AMIDO ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100061960-A1 | Amido Anti-Viral Compounds, Compositions, And Methods Of Use | SCHMITZ FRANZ ULRICH | 2010-03-11 | — | — | US | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100061960-A1 | Amido Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, OAT, MAVS | DPP4 167/4885ALDH1A1 4853/4885SMN1; SMN2 126/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | DPP4 1413/4885ALDH1A1 170/4885SMN1; SMN2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.